16.5 million US adults live with atopic dermatitis, yet only the roughly 40% with moderate-to-severe disease enter the biologic-eligible commercial segment.

Atopic dermatitis is a chronic, relapsing, type 2 inflammatory skin disease driven by a weakened skin barrier and by IL-4, IL-13 and IL-31 cytokine signalling. It affects an estimated 16.5 million US adults, roughly 7% adult prevalence, and more than 9.6 million US children. Diagnosis is entirely clinical since there is no confirmatory lab biomarker, anchored on standard criteria, with severity graded by validated instruments such as EASI, IGA and SCORAD. Endotype heterogeneity across age, ethnicity and skin-barrier gene status increasingly informs which targeted therapy a patient receives.

Severity distribution is the commercial pivot. Most patients have mild disease managed with emollients and topical treatment, while approximately 40% of adults, roughly 6.6 million, have moderate-to-severe disease that topical therapy fails to control, the population eligible for systemic biologics and oral JAK inhibitors. Atopic dermatitis is typically the first step of the atopic march, often preceding food allergy, asthma and allergic rhinitis in children, though recent evidence shows the sequence is not as fixed as once assumed. This moderate-to-severe, topical-refractory segment is where dupilumab's roughly 70% biologic share and the JAK step-edit landscape actually play out.

Only the topical-refractory 40% ever reach a biologic or JAK prescription.

Five questions this report answers:

Q1 - How large is the moderate-to-severe, biologic-eligible US atopic dermatitis population?

Q2 - How is atopic dermatitis diagnosed and severity-graded in US practice?

Q3 - How does the atopic march shape long-term patient segmentation and value?

Q4 - How many US adults and children live with atopic dermatitis?

Q5 - What clinical criteria and severity scores define an atopic dermatitis diagnosis?

Share your commercial question with us. We'll align on scope — then build the right intelligence around it.

→ moatrx.com/axlrx.html

#AtopicDermatitis #Eczema #Dermatology #Dupixent #USHealthcare #DiseaseLandscape

Live report page:  https://axlrx.ai/atopic-dermatitis/disease-landscape/

Thanks & Regards,

Mike || Global Pharma Commercial Marketing Head

Email-           hello@axlrx.ai

Web-           https://axlrx.ai/